Nuventra, Inc. ( Nuventra)

×

Status message

SESSION['ACCESSGRANTED'] value is

Primary tabs

Nuventra's picture

Management

Contact Address

About Nuventra, Inc.

Nuventra, Inc. is a clinical pharmacology consulting firm specializing in pharmacokinetics (PK), pharmacodynamics (PD), and pharmacometrics (popPK). The pharmaceutical industry’s ‘go-to’ resource for PK/PD, Nuventra gives pharmaceutical companies and CROs rare access to a hands-on team of leading clinical pharmacology and PK/PD professionals experienced in a multitude of therapeutic areas and using leading PK/PD analysis software. We embrace the notion that simplicity and clarity lead to good decisions by taking complex pharmacokinetic principals and making them understandable and usable for common sense drug development. Nuventra’s flexible business structure enables our expert consultants to integrate within our clients’ R&D group and help them maximize the potential of clinical pharmacology studies and PK analyses to pave the way toward marketing approval.

Nuventra press release, blog etc

Mon, 05/02/2022 - 20:43 Nuventra is now Allucent
Thu, 02/24/2022 - 21:20 Nuventra Scientists Author Top Downloaded Journal Article in Clinical Pharmacology & Therapeutics in 2021
Tue, 02/15/2022 - 22:43 Navigating Regulatory Strategies for Cellular & Gene Therapies
Wed, 08/18/2021 - 22:54 Nuventra Ranks on Inc. 5000 List for Eighth Consecutive Year
Wed, 05/26/2021 - 15:30 CATO SMS Acquires Nuventra to Expand Drug Development Offering Into Clinical Pharmacology
Wed, 03/31/2021 - 10:16 Nuventra Announces PK/PD Innovation Fellowship with UNC Chapel Hill for the Advancement of Minorities in the Pharmaceutical Sciences
Mon, 03/01/2021 - 16:28 Nuventra Client G1 Therapeutics Receives FDA Approval for COSELA
Fri, 02/12/2021 - 16:17 Nuventra to Speak at PBSS Symposium on Cardiac Safety for Preclinical and Clinical Development
Mon, 09/07/2020 - 04:13 Nuventra to Present on QSP and PBPK at this Years ACCP Virtual Roundtable
Thu, 08/13/2020 - 16:57 Nuventra Ranks on Inc. 5000 List for Seventh Consecutive Year
Mon, 08/10/2020 - 16:00 Former FDA Reviewer Suliman Al-Fayoumi Joins Nuventra Pharma Sciences as Senior Consultant
Thu, 05/07/2020 - 12:07 Nuventra Scientists Publish Manuscript Discussing the Feasibility of Ivermectin as a Treatment for SARS-CoV-2
Tue, 02/04/2020 - 22:31 Nuventras Brian Furmanski to Speak at the Drug Metabolism Discussion Group Winter Symposium
Tue, 01/28/2020 - 19:23 Nuventra to Speak at PBSS San Francisco Symposium: Development of Drug/Device Combinations
Mon, 10/28/2019 - 11:53 Former FDA Reviewer Iftekhar Mahmood, Ph.D., Joins Nuventra Pharma Sciences as Senior Consultant
Mon, 09/30/2019 - 10:24 Nuventras Brian Furmanski to Present at AACP/AAPS Webinar, Navigating and Understanding FDA Review Documents
Wed, 08/14/2019 - 13:05 Nuventra Ranks on Inc. 5000 List for Sixth Consecutive Year
Fri, 04/26/2019 - 11:44 Nuventra Announces Addition of Chuck Poole and Howard A. Ball to its Growing Team of Clinical Pharmacology Experts